fda warning letters compounded semaglutide tirzepatide september 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding Beyond the Headlines: FDA Warning

When broken down by substance: Alcohol disorders 18% Cannabis disorders 14% Cocaine disorders 20% Nicotine disorders 20% Opioid disorders 25% Even more striking, among patients who already had addiction, GLP-1 therapy was associated with: 31% fewer emergency department visits 26% fewer hospitalizations 39% fewer overdoses 50% lower risk of death related to substance use

The savings are modest but real over the course of a year

A hallmark of IgAN is the accumulation of IgA-containing immune complexes in the glomerular mesangium

This article explores how GLP-1 works in the body to drive these outcomes, the differences between natural GLP-1 and synthetic agonists, and how to effectively navigate treatment options for sustainable health